InsiderTrades

Form 4 for ABOS Acumen Pharmaceuticals, Inc.

Accepted 2021-07-08 00:00:00 ET · period of report 2021-07-06 · accession 0001104659-21-090244 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMI 2021-07-08 2021-07-06 ABOS Shah Rajeev M. Dir, 10% P - Purchase $16.00 +1.88M 7.88M +31% +$30.00M
DMI 2021-07-08 2021-07-06 ABOS Shah Rajeev M. Dir, 10% C - Cnv Deriv — +7.90M 588.9K New —
DMI 2021-07-08 2021-07-06 ABOS Shah Rajeev M. Dir, 10% C - Cnv Deriv $0.00 -7.90M 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-07-06 P A 115,668 $16.00 1,300,034 I See footnotes — — (F3) These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). (F5) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
2 Common Common Stock 2021-07-06 C A 1,184,366 — 1,184,336 I See footnotes — — (F1) On July 6, 2021, each share of Series B Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F3) These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). (F5) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
3 Common Common Stock 2021-07-06 P A 1,759,332 $16.00 7,881,889 I See footnotes — — (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F5) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
4 Common Common Stock 2021-07-06 C A 6,122,557 — 6,122,557 I See footnotes — — (F1) On July 6, 2021, each share of Series B Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F5) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
5 Common Common Stock 2021-07-06 C A 588,850 — 588,850 I See footnotes — — (F1) On July 6, 2021, each share of Series B Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. (F4) These securities are held directly by a separately managed account (the "Account"). (F5) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
6 Derivative Series B Preferred Stock 2021-07-06 C D 6,122,557 $0.00 0 I See footnotes — · — to — 6,122,557 Common Stock (F2) These securities are held directly by RA Capital Healthcare Fund, L.P. (the "Fund"). (F5) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F1) On July 6, 2021, each share of Series B Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
7 Derivative Series B Preferred Stock 2021-07-06 C D 1,184,366 $0.00 0 I See footnotes — · — to — 1,184,366 Common Stock (F5) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F3) These securities are held directly by RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). (F1) On July 6, 2021, each share of Series B Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
8 Derivative Series B Preferred Stock 2021-07-06 C D 588,850 $0.00 0 I See footnotes — · — to — 588,850 Common Stock (F5) RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund II and the Account. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. (F4) These securities are held directly by a separately managed account (the "Account"). (F1) On July 6, 2021, each share of Series B Preferred Stock (the "Preferred Stock") converted into one share of Common Stock of the Issuer without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.